MedTrace Logo

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

NCT06196671 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of oncolytic virus plus PD-1 inhibitor to Patients with Advanced Pancreatic Cancer.

Conditions

Interventions

DRUG

H101

H101 15x10\^11vp intratumorally injection starts at day 1.

DRUG

Camrelizumab

Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-01
Primary Completion
2028-01-01
Completion
2028-01-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06196671 on ClinicalTrials.gov